Drug Database
Back to search

Poland· PL-100122013

Sylimarol Plus

A liver therapy product containing kompleks sylimarynowo-fosfolipidowy, registered in Poland by Poznańskie Zakłady Zielarskie "Herbapol" S.A.. The same ATC class is registered in 3 of our 19 countries.

ATC A05BA

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSylimarol PlusATCA05BAREGISTER NO.PL-100122013PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about kompleks sylimarynowo-fosfolipidowyAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Kompleks sylimarynowo-fosfolipidowy is registered in 3 of 19 countries.

Countries holding a registration under ATC A05BA (liver therapy), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose
Search kompleks sylimarynowo-fosfolipidowy products by name

Kompleks sylimarynowo-fosfolipidowy · ATC A05BA

3 / 19 countries

  • Belgiumprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Kompleks sylimarynowo-fosfolipidowy
Manufacturer
Poznańskie Zakłady Zielarskie "Herbapol" S.A.
Country
Poland (PL)
ATC code
A05BA
ATC class
Liver therapy
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

  • gtin
    05909991048518
  • gtin
    05909991048525
  • gtin
    05909990777723
  • gtin
    05904490002054
  • gtin
    05904490004744

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under A05BA

Liver therapy, as other registers publish it.

All kompleks sylimarynowo-fosfolipidowy products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bb968e8f-8102-47ae-9b68-76f07ee77e86
GET /v1/drugs/bb968e8f-8102-47ae-9b68-76f07ee77e86?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "05909991048518 ¦ OTC ¦ 22934\n40 tabl.\n05909991048525 ¦ OTC ¦ Skasowane ¦ 22935\n40 tabl. w pojemniku\n05909990777723 ¦ OTC ¦ 57913\n20 tabl.\n05904490002054 ¦ OTC ¦ Skasowane ¦ 84392\n10 tabl.\n05904490004744 ¦ OTC ¦ 164777\n45 tabl.",
  "substance": "Kompleks sylimarynowo-fosfolipidowy 100 mg",
  "common_name": "Kompleks sylimarynowo-fosfolipidowy",
  "pl_product_id": "100122013",
  "pozwolenie_nr": "10485",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about kompleks sylimarynowo-fosfolipidowy.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console